콘텐츠로 건너뛰기
Merck
  • IL-18 associated with lung lymphoid aggregates drives IFNγ production in severe COPD.

IL-18 associated with lung lymphoid aggregates drives IFNγ production in severe COPD.

Respiratory research (2017-08-24)
Emmanuel Briend, G John Ferguson, Michiko Mori, Gautam Damera, Katherine Stephenson, Natasha A Karp, Sanjay Sethi, Christine K Ward, Matthew A Sleeman, Jonas S Erjefält, Donna K Finch
초록

Increased interferon gamma (IFNγ) release occurs in Chronic Obstructive Pulmonary Disease (COPD) lungs. IFNγ supports optimal viral clearance, but if dysregulated could increase lung tissue destruction. The present study investigates which mediators most closely correlate with IFNγ in sputum in stable and exacerbating disease, and seeks to shed light on the spatial requirements for innate production of IFNγ, as reported in mouse lymph nodes, to observe whether such microenvironmental cellular organisation is relevant to IFNγ production in COPD lung. We show tertiary follicle formation in severe disease alters the dominant mechanistic drivers of IFNγ production, because cells producing interleukin-18, a key regulator of IFNγ, are highly associated with such structures. Interleukin-1 family cytokines correlated with IFNγ in COPD sputum. We observed that the primary source of IL-18 in COPD lungs was myeloid cells within lymphoid aggregates and IL-18 was increased in severe disease. IL-18 released from infected epithelium or from activated myeloid cells, was more dominant in driving IFNγ when IL-18-producing and responder cells were in close proximity. Unlike tight regulation to control infection spread in lymphoid organs, this local interface between IL-18-expressing and responder cell is increasingly supported in lung as disease progresses, increasing its potential to increase tissue damage via IFNγ.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Anti-IL18 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution